Over the past 8 years, MD Anderson has made significant contributions to cancer clinical cooperative group trials, including robust accrual, scientific and administrative leadership, and mentoring young faculty to participate in and lead these important national trials. These attributes will be applied to the emerging National Clinical Trial Network (NCTN) with even greater emphasis through this Network Lead Academic Participant (LAP) grant, with the following overall aims:
Aim 1) To provide robust participation in and accrual to Network group clinical trials targeting a broad range of adult patients with common as well as rare cancers;
Aim 2) To promote best practices in the conduct of NCTN-sponsored clinical research and ensure high quality and timely submission of clinical trial-related data and materials as required by specific protocols;
Aim 3) To provide scientific and administrative leadership within affiliated Network Groups, including protocol development, publication authorship, participation in Network committees / NCI Central IRB (CIRB), and attendance at Network Group meetings;
and Aim 4) To mentor junior faculty, research personnel, and trainees in the leadership, conduct, analysis, and reporting of NCTN and other clinical trials. This LAP utilizes a Multiple Principal Investigator (PI) Plan to apply the demonstrated and complementary cooperative group leadership skills and expertise of 3 investigators: Dr. Cathy Eng, Dr. Kelly Hunt, and Dr. Ritsuko Komaki. In addition, investigators representing the disciplines of pathology, diagnostic imaging, gynecological oncology, surgery, and translational research will play key roles In cooperative group trial conduct and mentorship of young faculty. Oversight of trial accrual and data quality, fund management, centralized communications, and administrative support will be coordinated through the LAP Operations Center under the leadership of an experienced Program Administrator. An Executive Committee will ensure timely inter-Network group communications, effective study prioritizations, review and resolution of any accrual obstacles or data quality issues, and identification of junior facult across the institution as candidates for mentorship and/or leadership roles in Network clinical trials or committees.

Public Health Relevance

The UT MD Anderson Cancer Center Network Lead Academic Participating (LAP) Site grant will provide scientific and administrative leadership to conduct cancer research within the clinical cooperative groups. With enhanced centralized coordination of related activities, this grant will assist with robust accrual across all cooperatie groups and will assist in the development of innovative cancer treatment options, including the conduct of multidisciplinary clinical trials.

Agency
National Institute of Health (NIH)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
1U10CA180858-01
Application #
8605951
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Internal Medicine/Medicine
Type
Hospitals
DUNS #
City
Houston
State
TX
Country
United States
Zip Code
77030
Giuliano, Armando E; Ballman, Karla; McCall, Linda et al. (2016) Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized T Ann Surg 264:413-20
Dickler, Maura N; Barry, William T; Cirrincione, Constance T et al. (2016) Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). J Clin Oncol 34:2602-9
Press, Oliver W; Li, Hongli; Schöder, Heiko et al. (2016) US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. J Clin Oncol 34:2020-7
Tevaarwerk, Amye J; Lee, Ju-Whei; Terhaar, Abigail et al. (2016) Working after a metastatic cancer diagnosis: Factors affecting employment in the metastatic setting from ECOG-ACRIN's Symptom Outcomes and Practice Patterns study. Cancer 122:438-46
Unger, Joseph M; Hershman, Dawn L; Arnold, Kathryn B et al. (2016) Stepwise development of a cancer care delivery research study to evaluate the prevalence of virus infections in cancer patients. Future Oncol 12:1219-31
Warner, Erica T; Ballman, Karla V; Strand, Carrie et al. (2016) Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426). Breast Cancer Res Treat 159:109-18
Moots, Paul L; O'Neill, Anne; Londer, Harold et al. (2016) Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397). Am J Clin Oncol :
Haas, Naomi B; Manola, Judith; Uzzo, Robert G et al. (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-16
Miller, Christopher A; Gindin, Yevgeniy; Lu, Charles et al. (2016) Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers. Nat Commun 7:12498
Moore, Halle C F; Unger, Joseph M; Phillips, Kelly-Anne et al. (2015) Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 372:923-32

Showing the most recent 10 out of 14 publications